Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Prestige Consumer Healthcare's EBIT per Share for the
three
months ended in Jun. 2026 was $1.10.
Its EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2026 was $5.81.
During the past 12 months, the average EBIT per Share Growth Rate of Prestige Consumer Healthcare was -13.80% per year.
During the past 3 years, the average EBIT per Share Growth Rate was -3.10% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 1.50% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 6.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Prestige Consumer Healthcare's EBIT per Share or its related term are showing as below:
PBH'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -36.2 Med: 8.2 Max: 82.1
Current: -3.1
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Prestige Consumer Healthcare was 82.10% per year. The lowest was -36.20% per year. And the median was 8.20% per year.
PBH's 3-Year EBIT Growth Rate is ranked worse than 66.17% of 810
companies
in the Drug Manufacturers industry
Industry Median: 7.5
vs PBH: -3.10
Prestige Consumer Healthcare (NYSE:PBH) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Prestige Consumer Healthcare EBIT per Share Related Terms
Prestige Consumer Healthcare EBIT per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $5.81
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Prestige Consumer Healthcare (PBH) has a EBIT per Share of $5.81 as of Jun. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Prestige Consumer Healthcare and its competitors. According to the industry distribution chart, Prestige Consumer Healthcare ranks #536 out of 810 companies in the Drug Manufacturers industry, placing it in the top 66.2%.
Is Prestige Consumer Healthcare's EBIT per Share too high?
Prestige Consumer Healthcare's current EBIT per Share is $5.81. The Drug Manufacturers industry median EBIT per Share is 7.50. Prestige Consumer Healthcare's value of $5.81 is 22.5% below this industry median. Based on the distribution chart, Prestige Consumer Healthcare ranks #536 out of 810 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Prestige Consumer Healthcare has a GF Score™ of 69/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Prestige Consumer Healthcare's EBIT per Share compare to BCRX and AMLX?
According to the Drug Manufacturers industry distribution chart, Prestige Consumer Healthcare ranks #536 out of 810 companies for EBIT per Share. This places Prestige Consumer Healthcare in the lower half of its industry. The industry median EBIT per Share is 7.50. Prestige Consumer Healthcare's value of $5.81 is 22.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Drug Manufacturers company?
The median EBIT per Share among Drug Manufacturers companies is 7.50, based on 810 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Prestige Consumer Healthcare's current EBIT per Share of $5.81 is 22.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Prestige Consumer Healthcare and its competitors. For the Drug Manufacturers industry, the median EBIT per Share is 7.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Prestige Consumer Healthcare's current EBIT per Share is $5.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prestige Consumer Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Prestige Consumer Healthcare (PBH) is currently considered Modestly Undervalued. The stock's GF Value™ is $70.51, compared to a current price of $50.52 — trading 28.4% below its estimated fair value. The current EBIT per Share is $5.81 and 22.5% below the Drug Manufacturers industry median of 7.50. Prestige Consumer Healthcare's overall GF Score™ is 69/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Prestige Consumer Healthcare (PBH), the current EBIT per Share is $5.81 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Prestige Consumer Healthcare (PBH) Overvalued in 2026?
Based on GuruFocus' analysis, Prestige Consumer Healthcare stock appears to be undervalued.
The current stock price of $50.52 is trading 28.4% below its estimated GF Value™ of $70.51.
GuruFocus considers Prestige Consumer Healthcare to be Modestly Undervalued.
Key valuation signals for PBH:
EBIT per Share: $5.81
GF Value™: $70.51 vs. price of $50.52 (28.4% below fair value)
Industry Position: 22.5% below the Drug Manufacturers median (#536 of 810)
No single metric tells the full story. See the PBH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige's key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer's Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.
69GF Score
Get the complete analysis for PBH
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PBH has been successfully added to your 
